ATNMActinium PharmaceuticalsATNM info
$1.89info5.00%24h
Global rank25031
Market cap$51.81M
Change 7d-3.57%
YTD Performance-63.44%
SP500 benchmarkUnderperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Actinium Pharmaceuticals (ATNM) Stock Overview

    Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple targets in oncology and hematology, including CD45, CD33, HER3, and other. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company is based in New York, New York.

    ATNM Stock Information

    Symbol
    ATNM
    Address
    275 Madison AvenueNew York, NY 10016United States
    Founded
    -
    Trading hours
    -
    Website
    https://www.actiniumpharma.com
    Country
    πŸ‡ΊπŸ‡Έ United States
    Phone Number
    646 677 3870

    Actinium Pharmaceuticals (ATNM) Price Chart

    -
    Value:-

    Actinium Pharmaceuticals Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $1.89
    N/A
    Market Cap
    $51.81M
    N/A
    Shares Outstanding
    27.41M
    N/A
    Employees
    49.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org